EP Patent

EP0785212A1 — New 19-nor-pregnene derivatives

Assigned to Laboratoire Theramex SAM · Expires 1997-07-23 · 29y expired

What this patent protects

The invention relates to compounds of the formula : wherein : R 1 , R 2 , R 3 , R 4 and R 6 each independently represent hydrogen or a (C 1 -C 6 )alkyl, R 5 is hydrogen, a (C 1 -C 6 )alkyl or a group -COR 7 where R 7 is a (C 1 -C 6 )alkyl, n is zero or one, an…

USPTO Abstract

The invention relates to compounds of the formula : wherein : R 1 , R 2 , R 3 , R 4 and R 6 each independently represent hydrogen or a (C 1 -C 6 )alkyl, R 5 is hydrogen, a (C 1 -C 6 )alkyl or a group -COR 7 where R 7 is a (C 1 -C 6 )alkyl, n is zero or one, and X is oxygen or an hydroxyimino group, provided that when n = 0, at least two of R 1 , R 2 , R 3 and R 4 are different from hydrogen and that when n = 1, R 3 and R 4 are not simultaneously hydrogen, and to pharmaceutical compositions containing them. These compounds are excellent progestogens and are devoid of residual androgenic activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP0785212A1
Jurisdiction
EP
Classification
—
Expires
1997-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Laboratoire Theramex SAM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.